

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**VOLUNTARY ANNOUNCEMENT
UPDATED INFORMATION OF THE GROUP'S PRODUCTS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors of the Company is pleased to announce that it was informed by China State Food and Drug Administration that the applications of the Group's insulin glargin bulk medicine and insulin glargin finished product have been approved with approval number of S20160010 and S20160009 respectively. The approved insulin glargin product is the specification of refilled pen-type injection. It is expected that the relevant insulin products will be launched to the market soon.

Insulin glargin is a long-acting insulin analog of the third generation insulin products. In addition, the Group's four recombinant human insulin finished products of the second generation insulin (including the four specifications: N, R, 30R and 50R) have been launched to the market in 2011. After the approval of insulin glargin, the Group is the pharmaceutical enterprise of the second and third generation insulin products in China. Apart from the products mentioned above, the Group's insulin products in R&D also cover insulin aspart, insulin detemir, insulin degludec, etc. It is expected that the above products will be launched to the market gradually so that the Group's insulin pipeline will be enriched and will bring considerable return to the Company and its shareholders in future.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 6 January 2017

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.